Drug regulators in Europe have discovered no proof that common diabetes and weight-loss medicine like Ozempic and Wegovy are linked to a better danger of suicidal ideas or actions.
The European Medicines Company regulatory committee introduced the outcomes of its overview on Friday. It’s the most recent group to conclude there’s no recognized tie between a brand new class of weight problems medicine and suicide.
In January, the U.S. Meals and Drug Administration stated a preliminary overview confirmed no proof of such a hyperlink, although the company stated it couldn’t rule out that “a small danger could exist” and that it could proceed to check the difficulty. A federally funded U.S. examine additionally discovered that individuals taking semaglutide, the medicine in Ozempic and Wegovy, had a decrease danger of suicidal ideas than these taking older medicines to deal with diabetes and weight problems.
The overview by the European Union’s regulators was triggered final July by anecdotal stories that individuals taking the medicine had ideas of self-harm. The regulators examined research, post-marketing knowledge and different analysis associated to medicines utilized in almost a dozen medicine used to deal with the ailments. The group didn’t overview data concerning tirzepatide, the medicine utilized in medicine bought as Mounjaro and Zepbound.
Each businesses stated they’d proceed to carefully monitor stories of suicidal ideas or actions in folks taking the medicine referred to as GLP-1 receptor agonists. Sufferers taking the medicine ought to report any psychological well being or different issues to their well being care suppliers, officers stated.
© 2024 The Canadian Press
